Solvonis Therapeutics plc (LON:SVNS)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.1645
-0.0055 (-3.24%)
Jul 20, 2026, 3:38 PM GMT
Market Cap11.57M -43.8%
Revenue (ttm)n/a
Net Income-5.74M
EPS-0.00
Shares Out 6.81B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,722,694
Open0.1656
Previous Close0.1700
Day's Range0.1600 - 0.1700
52-Week Range0.1560 - 0.4000
Beta1.21
Analystsn/a
Price Targetn/a
Earnings DateSep 11, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorde... [Read more]

Founded 2017
Employees 6
Stock Exchange London Stock Exchange
Ticker Symbol SVNS
Full Company Profile

Financial Performance

Financial Statements